The UK breast screening program - what you need to know.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or synthesis methodology
PubMed 28661704 · doi:10.1080/13697137.2017.1342619
What was done
This is a narrative review designed for non-breast specialist healthcare professionals. The abstract describes an overview of the nearly 30-year evolution of the UK breast screening program, current diagnostic methods, evidence regarding benefits and potential harms, and prospective changes to screening strategies and imaging techniques.
What was found
The abstract reports that breast cancer is the most common cancer in women with a UK lifetime risk of 1 in 8. No quantitative data, effect sizes, or specific statistics regarding the magnitude of benefits or harms are provided in the abstract.
Why it matters
It offers clinicians a broad contextual summary of breast screening implementation, clinical utility, and the trade-offs between cancer detection and screening harms in the UK health system.
Limits
As a narrative review, it does not employ systematic review methods or formal quality appraisal. The abstract contains no primary empirical data, study counts, or quantitative estimates of screening outcomes.
Cited by
- supports Approximately 12% of women will develop breast cancer in their lifetime, while 88% will not.